Hormones and mood: the neurobiology women don't get explained

Three days before your period, you sit on the floor and cry because the dishwasher is full. Six days later you feel completely fine and cannot understand what that was about.

If that pattern is familiar, you are not unstable. You are responding to a measurable, mechanistic interaction between your reproductive hormones and the parts of your brain that regulate mood. The honest scientific position on this is no longer in doubt. The question is not whether hormones affect mood. The question is which hormones, through which pathways, in which women, and what to do about it.

This article walks through the neurobiology of the estrogen-mood link and the progesterone-mood link, the distinction between PMS and PMDD, what the evidence-backed interventions actually are, and how to think about your own pattern.

The thing women don't usually get told

Women are told their PMS is hormonal. That is true and not very useful, because it implies hormone levels are off. The newer and better understanding is this:

Women with cycle-related mood symptoms generally have normal hormone levels. What differs is their brain's sensitivity to normal hormonal fluctuations ^[1][2].

This distinction is not pedantic. It changes how the problem is framed. You are not low on something. You are not "imbalanced." Your nervous system is reacting more strongly to the same hormonal shifts that other women's nervous systems handle with less visible effect. It is a sensitivity story, not a deficiency story, and the practical implications are different.

Two main hormone-brain interactions drive most of the cycle-mood story.

Mechanism 1: estrogen and serotonin

Serotonin is the neurotransmitter most associated with mood, motivation, social engagement, and impulse regulation. It is also the target of the most-prescribed class of antidepressants (SSRIs).

Estrogen has a direct, well-mapped effect on the serotonin system. It promotes serotonin synthesis, prevents its degradation, inhibits its reuptake, and promotes the expression of serotonin receptors ^[3]. In effect, higher estrogen behaves like a mild SSRI in your brain.

This is why many women report their best cognitive and emotional functioning in the late follicular phase, when estrogen is rising toward its mid-cycle peak. Energy, confidence, social ease, libido, mental clarity. The estrogen rise is doing real work on serotonin transmission.

The flip side is the drop. Estrogen falls sharply twice in a typical cycle: just after ovulation (a smaller dip), and in the late luteal phase before menstruation (a steeper drop). For women whose brains are sensitive to these drops, mood follows. The premenstrual mood slump is, at its core, an estrogen-withdrawal phenomenon at the level of serotonin signalling.

This is the same mechanism that explains postpartum mood difficulties and perimenopausal depression. Estrogen rises 100 to 1000-fold during pregnancy and crashes within days of giving birth ^[4]. In perimenopause, estrogen does not just fall, it fluctuates wildly. Both situations replicate the same physiological event the late luteal phase produces, just at much larger amplitude. Women with histories of PMS-related mood symptoms are at higher risk of postpartum depression and perimenopausal depression for this reason: their brains are sensitive to estrogen drops, and the reproductive lifespan delivers multiple opportunities for those drops ^[5].

Mechanism 2: progesterone, allopregnanolone, and the GABA twist

The other major hormone in the luteal phase is progesterone. Your body converts progesterone into a neurosteroid called allopregnanolone, which is a positive allosteric modulator of the GABA-A receptor ^[6]. GABA is your brain's main inhibitory (calming) neurotransmitter. When allopregnanolone binds to GABA receptors, it enhances their calming effect.

For most women, this is a good thing. Allopregnanolone has anxiolytic, sedative, and antidepressant-like effects. In the luteal phase, when allopregnanolone rises, many women feel calmer, sleepier, more inward.

For a meaningful minority of women, the response goes in the opposite direction. The same allopregnanolone rise that produces calm in most women produces anxiety, irritability, and depressed mood in them. This is the "paradoxical" GABA response, and it is one of the leading mechanisms proposed for PMDD ^[7].

The proposed reason: GABA-A receptors come in several configurations, and the δ-subunit variant is particularly responsive to allopregnanolone. Women with PMDD appear to have altered expression or sensitivity of the δ-subunit during the luteal phase, which means the same dose of allopregnanolone that calms a typical brain agitates theirs ^[8]. This is a real biological difference, not a willpower problem.

The allopregnanolone-GABA story also explains the postpartum picture. During pregnancy, allopregnanolone rises with progesterone. Within hours of delivery, it crashes. The GABA system, which had adapted to high tonic allopregnanolone for nine months, is suddenly destabilised. The anxiety, sleeplessness, and mood disturbances of the early postpartum period are partly the GABA system recalibrating ^[4].

PMS vs PMDD: the distinction worth knowing

Medical disclaimer. PMDD is a recognised psychiatric diagnosis in the DSM-5 that requires clinical evaluation, ideally by a clinician familiar with women's mental health. The diagnostic criteria require prospective daily symptom tracking confirmed across at least two cycles. Nutrition and lifestyle interventions can support general premenstrual mood symptoms but cannot replace evidence-based treatment (SSRIs, CBT, hormonal interventions) for diagnosed PMDD.

These two diagnoses get confused, often by clinicians as well as patients.

PMS (premenstrual syndrome) affects most menstruating women to some degree. Symptoms appear in the luteal phase, resolve within a few days of menstruation, and include mood changes, irritability, breast tenderness, bloating, cravings, and fatigue. It is uncomfortable but generally manageable and does not significantly impair functioning.

PMDD (premenstrual dysphoric disorder) is a distinct diagnosis in the DSM-5 and affects roughly 3 to 8% of menstruating women, with prevalence estimates ranging up to 10% depending on diagnostic criteria ^[9]. The symptoms are similar to PMS but more severe: marked depression, anxiety, irritability, anger, with significant functional impairment in work, relationships, or daily life. The diagnostic criterion requires symptoms to be present in most cycles, confined to the luteal phase, with substantial improvement within a few days of menstruation, and confirmed by prospective tracking over at least two cycles.

PMDD is not a more severe form of PMS in the sense of "the same thing, worse." The mechanism appears to be specifically the paradoxical allopregnanolone response combined with serotonin sensitivity, both more pronounced than in typical PMS.

If your cycle-related mood symptoms are interfering with your relationships, work, or quality of life, PMDD is a real diagnosis worth raising with a doctor. SSRIs are effective for PMDD with a faster onset than for depression (typically 1 to 2 days vs 4 to 6 weeks), and luteal-phase-only dosing is a recognised treatment strategy ^[10].

What the evidence supports for cycle-related mood

There are several intervention categories with research behind them. Honest summary by strength of evidence:

Strong evidence

SSRIs. For PMDD specifically, SSRIs are the first-line pharmacological treatment. Sertraline, paroxetine, fluoxetine, and escitalopram are all evidence-supported. Can be taken continuously or only in the luteal phase ^[10]. This is a medical decision and requires a prescription.

Cognitive behavioural therapy (CBT). Demonstrated to reduce PMS and PMDD symptoms in randomised trials. Particularly effective in combination with other interventions.

Moderate evidence

Vitamin B6. A 2025 systematic review of 31 randomized controlled trials in 3,254 participants concluded that vitamin B6 at doses of at least 50 mg/day produces consistent positive effects on PMS mood symptoms, including irritability, anxiety, and mood ^[11]. The mechanism is B6's role as a cofactor in serotonin and GABA synthesis.

Calcium. The same 2025 systematic review found all four reviewed trials of calcium showed positive impacts on PMS symptoms ^[11]. The dose used in most trials is around 1000 to 1200 mg/day, typically combined with vitamin D.

Magnesium (especially combined with B6). A randomised double-blind crossover study showed that 200 mg/day of magnesium combined with 50 mg/day of vitamin B6 produced a significant decrease in anxiety-related premenstrual symptoms compared to either supplement alone ^[12].

Some evidence

Omega-3 fatty acids. Multiple RCTs and the 2022 Mohammadi et al. meta-analysis in J Obstet Gynaecol Res suggest omega-3 reduces both physical and psychological PMS symptoms (see our Omega-3 article for the full data).

Exercise. Aerobic exercise consistently improves PMS symptoms in trials, with the largest effects on physical and mood symptoms. Mechanism likely combines endorphin release, sleep improvement, and inflammation reduction.

Sleep hygiene. Sleep quality predicts mood the next day, and PMS symptoms predict worse sleep. The two reinforce each other. Improving sleep tends to improve mood across the cycle.

Weak or mixed evidence

Chasteberry (Vitex agnus-castus). Some positive trials, mostly small or with methodological limitations. Mechanism unclear (proposed action on dopamine and prolactin). Worth knowing about; not strongly supported.

Evening primrose oil. Limited evidence for mood symptoms specifically. Modest evidence for breast tenderness.

Lifestyle approaches (caffeine reduction, alcohol reduction). Mixed evidence at the trial level for prevention, but individual responses vary. For acute symptom worsening, these are worth experimenting with (see our Coffee and Alcohol articles for the mechanisms).

What this means for the nōuxx routine

The nōuxx cycle routine contains several of the moderate-evidence nutrients in their relevant phases:

• B6 is present across phases as part of the B-complex baseline
• Magnesium is in Calm Choco, the luteal-phase variant, at clinically relevant levels paired with co-factors that support nervous system function
• Calcium is in the formulation
• L-tryptophan is included, a precursor to serotonin

This is not coincidence. The luteal-phase formulation was built around the nutritional inputs most strongly linked to mood regulation in the cycle phase where mood symptoms peak. The routine is not a treatment for PMDD or clinical depression. For sub-clinical PMS-range symptoms, the nutritional levers are real and supported by the research above.

If your symptoms are at the PMDD end of the spectrum (substantial functional impairment), nutrition is a support layer, not a primary intervention. SSRIs and CBT remain the first-line treatments with the strongest evidence.

How to figure out your own pattern

The single highest-leverage tool: prospective cycle tracking.

Symptoms remembered after the fact are unreliable. Mood, energy, and physical symptoms tracked daily for 2 to 3 full cycles produce a far clearer picture than memory. You start to see:

• Whether your mood symptoms are actually cycle-linked or background
• Which days of the cycle they cluster on
• Which co-occurring symptoms (sleep, cravings, energy) move with mood
• Whether interventions are actually changing the pattern

A simple paper tracker works. So do apps (Clue, Flo, Natural Cycles, Stardust). The point is consistency, not the platform. Two to three months of daily tracking is enough to see your own pattern.

This is also the diagnostic standard for PMDD. The DSM-5 criterion requires prospective daily tracking over two cycles. If you suspect PMDD and want to raise it with a doctor, two months of tracking strengthens the conversation considerably.

Common questions

Are my mood swings "real" or in my head?

The hormone-brain mechanisms above are real, measurable, and documented in primary literature including animal models, human imaging, and randomised intervention trials. "In your head" and "real" are not opposites. Your brain is in your head. What is happening to it is biology.

Why do some women get PMDD and others don't?

Genetics, GABA-A receptor subunit expression, baseline serotonin sensitivity, stress exposure, and life history all appear to contribute. There is no single explanation. NIH research has identified an altered gene complex in PMDD patients that processes the body's response to sex hormones and stress ^[13]. This is biology, not weakness.

Should I take birth control to "stabilise" my mood?

Some women report improved mood on combined oral contraceptives because the cyclical hormonal fluctuation is suppressed. Others report worse mood. The evidence is mixed (see our Pill article for the full picture). For some women with PMDD, continuous (no-bleed) regimens can be helpful by eliminating the cyclical drop entirely. This is a discussion with your doctor.

Can I just take an SSRI in the luteal phase?

For diagnosed PMDD, luteal-phase-only SSRI dosing is an evidence-based approach. SSRIs work faster for PMDD than for depression (1 to 2 days vs 4 to 6 weeks), which is what makes intermittent dosing viable. This requires a prescription and a proper PMDD diagnosis. Not a DIY intervention.

What if my mood symptoms are getting worse with age?

Perimenopause (typically starting in the late 30s to mid-40s) brings increasingly volatile estrogen levels. Women with a history of PMS-related mood symptoms or postpartum depression are at higher risk of perimenopausal mood symptoms because the underlying hormone-sensitivity profile is shared. If your cycle-mood pattern is intensifying in your late 30s or 40s, this is worth discussing with a doctor, particularly one familiar with the menopause transition.

Will the routine fix my PMS?

The honest answer: for sub-clinical PMS symptoms, the nutrients in the routine are evidence-supported and can produce meaningful improvement. For PMDD-level symptoms, the routine is a supportive layer, not a treatment. Use the cycle tracking exercise above to see where on the spectrum you actually sit.

What about postpartum?

The same mechanisms apply at much larger amplitude. If you have a history of cycle-related mood symptoms, flagging this to your maternity care provider during pregnancy is worth doing. Postpartum mood difficulties are common, treatable, and not your fault. Reach out early if symptoms persist beyond the first couple of weeks.

The bottom line

Hormones do not "cause" mood swings by being abnormal. They affect mood through specific neurotransmitter mechanisms (estrogen on serotonin, allopregnanolone on GABA), and women vary in how sensitive their brains are to normal hormonal fluctuations. The mood pattern you experience around your cycle is biology, not character.

There is real treatment evidence at multiple levels: SSRIs and CBT for the severe end (PMDD), nutritional support (B6, magnesium, calcium, omega-3) for the moderate range, and behavioural levers (sleep, exercise, alcohol moderation, caffeine timing) across the board.

The most powerful single move is tracking your own pattern for two cycles. The data will tell you which interventions actually move your needle. The rest follows from there.

References

[1] Harvard Health Publishing. Premenstrual dysphoria disorder: It's biology, not a behavior choice. Harvard Health Blog 2017. health.harvard.edu/blog/premenstrual-dysphoria-disorder-its-biology-not-a-behavior-choi...

[2] Hantsoo L, Payne JL. Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA. Neuroscience and Biobehavioral Reviews 2023;149:105168. doi.org/10.1016/j.neubiorev.2023.105168

[3] Wharton W, et al. Neurobiological Underpinnings of the Estrogen - Mood Relationship. Current Psychiatry Reviews 2012;8(3):247-256. doi.org/10.2174/157340012800792957

[4] Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. CNS Spectrums 2014;20(1):48-59. doi.org/10.1017/s1092852914000480

[5] Turek J, Gąsior Ł. Estrogen fluctuations during the menopausal transition are a risk factor for depressive disorders. Pharmacological Reports : PR 2023;75(1):32-43. doi.org/10.1007/s43440-022-00444-2

[6] Stefaniak M, et al. Progesterone and Its Metabolites Play a Beneficial Role in Affect Regulation in the Female Brain. Pharmaceuticals (Basel, Switzerland) 2023;16(4). doi.org/10.3390/ph16040520

[7] Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiology of Stress 2020;12:100213. doi.org/10.1016/j.ynstr.2020.100213

[8] Gao Q, et al. Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder: Toward precise targets for translational medicine and drug development. Frontiers in Psychiatry 2023;14. doi.org/10.3389/fpsyt.2023.1140796

[9] Naik SS, et al. Diagnostic validity of premenstrual dysphoric disorder: revisited. Frontiers in Global Women's Health 2023;4. doi.org/10.3389/fgwh.2023.1181583

[10] Harvard Health Publishing. Treating Premenstrual Dysphoric Disorder. Harvard Women's Health Watch 2024. health.harvard.edu/womens-health/treating-premenstrual-dysphoric-disorder

[11] Robinson J, et al. Effect of nutritional interventions on the psychological symptoms of premenstrual syndrome in women of reproductive age: a systematic review of randomized controlled trials. Nutrition Reviews 2024;83(2):280-306. doi.org/10.1093/nutrit/nuae043

[12] De Souza MC, et al. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. Journal of Women's Health & Gender-based Medicine 2000;9(2):131-139. doi.org/10.1089/152460900318623

[13] Hantsoo L, Payne JL. Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA. Neuroscience and Biobehavioral Reviews 2023;149:105168. doi.org/10.1016/j.neubiorev.2023.105168

[14] Hedges VL, et al. Estrogen Withdrawal Increases Postpartum Anxiety via Oxytocin Plasticity in the Paraventricular Hypothalamus and Dorsal Raphe Nucleus. Biological Psychiatry 2021;89(9):929-938. doi.org/10.1016/j.biopsych.2020.11.016

[15] Pouteau E, et al. Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial. Plos One 2018;13(12):e0208454. doi.org/10.1371/journal.pone.0208454

[16] Stiernman L, et al. Emotion-induced brain activation across the menstrual cycle in individuals with premenstrual dysphoric disorder and associations to serum levels of progesterone-derived neurosteroids. Translational Psychiatry 2023;13(1). doi.org/10.1038/s41398-023-02424-3